Overview of the latest selling price and efficacy of lorlatinib in 2024

Lorlatinib , as a powerful oral small molecule targeted drug, is widely used to treat ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). This third-generation ALK inhibitor can effectively inhibit ALK, ROS1 and < The activity of span>EGFRfamily is particularly suitable for patients who have developed resistance or intolerance to other ALK and ROS1 inhibitors.

Currently, lorlatinib (lorlatinib) has been launched in the domestic market and has been included in the medical insurance system, but the purchase price is still high, generally ranging from 10,000 to 20,000 yuan. For specific costs after medical insurance reimbursement, please consult your local hospital or pharmacy. In addition, overseas markets also offer lorlatinib (lorlatinib) options, including relatively affordable Turkish original drugs and drugs from Hong Kong, China, with prices of more than 7,000 yuan and 30,000 yuan respectively. In terms of generic drugs, the versions in Laos and Bangladesh are more affordable, ranging from more than a thousand yuan to several thousand yuan, and their efficacy is basically the same as the original drugs.

Lorlatinib blocks signaling by inhibiting ALK and ROS1 proteins in tumor cells, thereby curbing tumor growth. Compared with the previous two generations of ALK inhibitors, its targeting and inhibition capabilities are better and can effectively overcome drug resistance.

After clinical verification, lorlatinib has a significant effect on ALK and ROS1 positive NSCLC patients. A large clinical trial showed that its effective rate for patients with ALK positive NSCLC exceeded 60%, and some patients even achieved stable remission that lasted for several years. Although drugs may cause side effects such as visual disturbances, gastrointestinal discomfort, and abnormal liver function, they can usually be controlled by adjusting the dosage or symptomatic treatment.

It should be noted that lorlatinib is not suitable for all ALK and ROS1 positive NSCLC cases. Genetic testing is an integral step to determine patient suitability prior to use. At the same time, the patient's response needs to be closely monitored during medication so that the treatment plan can be adjusted in a timely manner.